The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study.
<h4>Background</h4>Randomized controlled trials (RCTs) have demonstrated a survival benefit for adjuvant platinum-based chemotherapy after resection of locoregional non-small cell lung cancer (NSCLC). The relative benefits and harms and optimal approach to treatment for NSCLC patients wh...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0263911 |
| _version_ | 1797843115777720320 |
|---|---|
| author | Amanda Leiter Chung Yin Kong Michael K Gould Minal S Kale Rajwanth R Veluswamy Cardinale B Smith Grace Mhango Brian Z Huang Juan P Wisnivesky Keith Sigel |
| author_facet | Amanda Leiter Chung Yin Kong Michael K Gould Minal S Kale Rajwanth R Veluswamy Cardinale B Smith Grace Mhango Brian Z Huang Juan P Wisnivesky Keith Sigel |
| author_sort | Amanda Leiter |
| collection | DOAJ |
| description | <h4>Background</h4>Randomized controlled trials (RCTs) have demonstrated a survival benefit for adjuvant platinum-based chemotherapy after resection of locoregional non-small cell lung cancer (NSCLC). The relative benefits and harms and optimal approach to treatment for NSCLC patients who have major comorbidities (chronic obstructive pulmonary disease [COPD], coronary artery disease [CAD], and congestive heart failure [CHF]) are unclear, however.<h4>Methods</h4>We used a simulation model to run in-silico comparative trials of adjuvant chemotherapy versus observation in locoregional NSCLC in patients with comorbidities. The model estimated quality-adjusted life years (QALYs) gained by each treatment strategy stratified by age, comorbidity, and stage. The model was parameterized using outcomes and quality-of-life data from RCTs and primary analyses from large cancer databases.<h4>Results</h4>Adjuvant chemotherapy was associated with clinically significant QALY gains for all patient age/stage combinations with COPD except for patients >80 years old with Stage IB and IIA cancers. For patients with CHF and Stage IB and IIA disease, adjuvant chemotherapy was not advantageous; in contrast, it was associated with QALY gains for more advanced stages for younger patients with CHF. For stages IIB and IIIA NSCLC, most patient groups benefited from adjuvant chemotherapy. However, In general, patients with multiple comorbidities benefited less from adjuvant chemotherapy than those with single comorbidities and women with comorbidities in older age categories benefited more from adjuvant chemotherapy than their male counterparts.<h4>Conclusions</h4>Older, multimorbid patients may derive QALY gains from adjuvant chemotherapy after NSCLC surgery. These results help extend existing clinical trial data to specific unstudied, high-risk populations and may reduce the uncertainty regarding adjuvant chemotherapy use in these patients. |
| first_indexed | 2024-04-09T16:59:32Z |
| format | Article |
| id | doaj.art-815904f40e294408a0e4e8bd05458a2d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T16:59:32Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-815904f40e294408a0e4e8bd05458a2d2023-04-21T05:33:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011711e026391110.1371/journal.pone.0263911The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study.Amanda LeiterChung Yin KongMichael K GouldMinal S KaleRajwanth R VeluswamyCardinale B SmithGrace MhangoBrian Z HuangJuan P WisniveskyKeith Sigel<h4>Background</h4>Randomized controlled trials (RCTs) have demonstrated a survival benefit for adjuvant platinum-based chemotherapy after resection of locoregional non-small cell lung cancer (NSCLC). The relative benefits and harms and optimal approach to treatment for NSCLC patients who have major comorbidities (chronic obstructive pulmonary disease [COPD], coronary artery disease [CAD], and congestive heart failure [CHF]) are unclear, however.<h4>Methods</h4>We used a simulation model to run in-silico comparative trials of adjuvant chemotherapy versus observation in locoregional NSCLC in patients with comorbidities. The model estimated quality-adjusted life years (QALYs) gained by each treatment strategy stratified by age, comorbidity, and stage. The model was parameterized using outcomes and quality-of-life data from RCTs and primary analyses from large cancer databases.<h4>Results</h4>Adjuvant chemotherapy was associated with clinically significant QALY gains for all patient age/stage combinations with COPD except for patients >80 years old with Stage IB and IIA cancers. For patients with CHF and Stage IB and IIA disease, adjuvant chemotherapy was not advantageous; in contrast, it was associated with QALY gains for more advanced stages for younger patients with CHF. For stages IIB and IIIA NSCLC, most patient groups benefited from adjuvant chemotherapy. However, In general, patients with multiple comorbidities benefited less from adjuvant chemotherapy than those with single comorbidities and women with comorbidities in older age categories benefited more from adjuvant chemotherapy than their male counterparts.<h4>Conclusions</h4>Older, multimorbid patients may derive QALY gains from adjuvant chemotherapy after NSCLC surgery. These results help extend existing clinical trial data to specific unstudied, high-risk populations and may reduce the uncertainty regarding adjuvant chemotherapy use in these patients.https://doi.org/10.1371/journal.pone.0263911 |
| spellingShingle | Amanda Leiter Chung Yin Kong Michael K Gould Minal S Kale Rajwanth R Veluswamy Cardinale B Smith Grace Mhango Brian Z Huang Juan P Wisnivesky Keith Sigel The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. PLoS ONE |
| title | The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. |
| title_full | The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. |
| title_fullStr | The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. |
| title_full_unstemmed | The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. |
| title_short | The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. |
| title_sort | benefits and harms of adjuvant chemotherapy for non small cell lung cancer in patients with major comorbidities a simulation study |
| url | https://doi.org/10.1371/journal.pone.0263911 |
| work_keys_str_mv | AT amandaleiter thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT chungyinkong thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT michaelkgould thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT minalskale thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT rajwanthrveluswamy thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT cardinalebsmith thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT gracemhango thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT brianzhuang thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT juanpwisnivesky thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT keithsigel thebenefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT amandaleiter benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT chungyinkong benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT michaelkgould benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT minalskale benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT rajwanthrveluswamy benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT cardinalebsmith benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT gracemhango benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT brianzhuang benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT juanpwisnivesky benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy AT keithsigel benefitsandharmsofadjuvantchemotherapyfornonsmallcelllungcancerinpatientswithmajorcomorbiditiesasimulationstudy |